Pancreatic cancer is an ailment in which malignant (cancerous) cells form in tissues of the pancreas. The pancreas is an organ that lies between the stomach and the spine. The pancreas produces stomach-related juices and hormones that direct glucose. Exocrine pancreas cells deliver stomach-related juices, while endocrine pancreas cells produce hormones. The pancreatic cancer generates mostly in exocrine cells. Globally, pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women. Early pancreatic cancer causes a few side-effects, a large number of which are indistinct. Since signs and indications of pancreatic cancer are mostly mistaken for less serious digestive disorders, the infection is only sometimes distinguished before it has spread to adjacent tissues or removed organs through the blood stream or lymphatic system. The pancreatic cancer spreads in five stages. From stage 0 to stage 5, cancerous cells spread in different tissue, blood stream, and lymphatic system. General symptoms of the pancreatic cancer include jaundice, pain in upper or middle abdomen, unexplained body weight, fatigue, and loss of appetite.

Based on treatment, the pancreatic cancer diagnostics market can be classified into surgery, chemotherapy, radiation therapy, and targeted therapy. Surgery and chemotherapy segments are expanding at a more rapid pace than radiation therapy and targeted therapy segments. This is due to the better clinical outcome and it offers realistic chances for cure. Based on test, the market has been segmented into imaging test, biopsy, and blood test. The imaging test segment holds the maximum market share, as imaging tests offer detection of cancer at an early stage. Based on end–user, the market has been segmented into hospitals, clinics, and research institutes. The hospitals segment is expanding at a rate higher than the other two segments. This growth is attributable to preference by patients to obtain complete treatment and availability of advanced tools and expertise. The market for pancreatic cancer diagnostics is expanding, due to increase in the consumption of alcohol and tobacco and changes in lifestyle. Moreover, high adoption of premium-priced drugs such as Abraxane injection and Gemzar to treat the pancreatic cancer boost the market. However, factors such as difficulty in diagnosis during the early stages, limited treatment options (especially when the disease has spread to other parts of the body), low success rates of clinical trials for anti-cancer drugs, and high cost associated with the treatment hamper the pancreatic cancer diagnostics market.

Geographically, the pancreatic cancer diagnostics market has been segmented into regions such as North America, Europe, Asia Pacific, and Middle East & Africa. North America hold the leading market share, due to associated with excessive alcohol use and gallstones. As estimated by SEER, 46,420 new pancreatic cancer cases were reported in the U.S. in 2014. Well-established health care infrastructure, demand for premium-priced drugs, and rapid marketing approvals of drugs boost the market in Europe. Multinational companies are making significant investments in developing economies in Asia to penetrate the untapped markets. Growing habit of smoking, improper diet, and genetics are major factors that drive the market in India. The Rest of the World includes the Middle East, Africa Changes in the medical practice, availability of a wide range of products, and increasing adoption of targeted therapies are likely to drive the pancreatic cancer diagnostics market in the region during the forecast period.

Some of the key players operating in the pancreatic cancer diagnostics market are Amgen, Inc., Celgene Corporation, Clovis Oncology, Inc., Eli Lilly and Company, Novartis AG, and Threshold Pharmaceuticals, Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Pancreatic Cancer Diagnostics Market

Pre Book